DC Department of Corrections
Washington D.C., District of Columbia, 20009, United States
NCT Number: NCT04560556
This is a prospective cohort study of outcomes of individuals who entered jail during a period during which one of three serial HIV testing strategies is implemented. This study involves two sub-studies. One sub-study will examine referrals to HIV prevention programs for persons testing negative for HIV while in jail. The second sub-study will monitor antiviral use among those testing positive for HIV.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Washington D.C., District of Columbia, 20009, United States
Incarcerated Americans on any given day represent one in 40 (2.5%) Persons Living with HIV (PLWH) in this country, but those ever incarcerated over the course of a year represent 17% of the US epidemic. PLWH are a diverse group in terms of awareness and management of their disease. A portion may be aware of their HIV status and on treatment. This subgroup is at risk of disruption in care if incarcerated. Others may be aware of their status, but untreated, while still others may be unaware of their HIV status. The latter group is of particular importance in terms of the HIV epidemic in criminal justice settings, as a recent meta-analysis indicated that up to 15% of individuals entering jail have undiagnosed infections.
Good management of PLWH during a period of incarceration is critical. Ensuring that care relationships are maintained or newly established will improve health outcomes among PLWH and reduce the risk of transmission once they are discharged. As the median length of stay in jail is short (median < 7 days), rapid HIV testing is critical. Maximizing the yield and speed of HIV testing in a jail environment has the potential to promote rapid entry into care, or rapid re-engagement if persons have fallen out of care. For those testing negative, it can hasten the referral to Pre-Exposure Prophylaxis (PrEP) services.
How correctional facilities offer HIV testing and begin treatment affects long-term outcomes. Because of the rapid churn of jail, point-of-care (POC) rapid testing may lead to a higher percentage of patients receiving test results before leaving jail, compared to conventional assays. Fourth generation laboratory-based antigen/antibody (Ag/Ab) testing can diagnosis more persons with acute HIV infection, who may be in the window period before the POC test turns positive, but has a several hour test turn-around time, and those tested may leave jail before receiving their result. Using both tests for every entrant would permit the jail to experience the benefit of both methods but at greater expense. Collaborating with Washington, DC's city jail, known as DC Department of Corrections (DC DOC), and Unity Healthcare, the network of Federally Qualified Health Centers in Washington DC, which also provides care within the DC DOC, this study has a unique opportunity to measure rapidity of testing, linkage to and commencement of care, and achievement of viral suppression, along with costs of HIV identification.
This study uses a unique, time-sensitive opportunity to compare three separate strategies of universal HIV screening and treating. The strategies of POC testing, 4th generation laboratory-based Ag/Ab testing, and a combination of the two tests will be compared in the DC jail. A rigorous assessment of the three strategies in terms of their feasibility, process measures, and cost-effectiveness on an institutional level will help to guide implementation decisions in jails across the US.
One sub-study will assess the number of persons testing negative who are referred to prevention programs after leaving the jail. A second sub-study will examine antiviral use after jail release, among PLWH.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for Those Testing Negative for HIV:
Inclusion criteria
for Those Testing Positive for HIV:
Exclusion criteria
Point-of-care (POC) rapid HIV testing provides results within minutes, however, it cannot reliably detect new infections. It can take up to 90 days after exposure for HIV infections to be diagnosed with POC rapid testing.
Fourth generation laboratory-based antigen/antibody (Ag/Ab) HIV testing can detect acute HIV infections (as early as 18 days after exposure), but it takes several hours to process.
Time frame: Up to 24 hours
The number of entrants receiving an HIV test within 24 hours of intake will be examined.
Time frame: Up to 24 hours
The percentage of PLWH identified within the first 24 hours of admission, among all PLWH who enter, will be examined.
Time frame: Up to Jail Discharge
The number of persons with a new diagnosis of HIV who receive test results before discharge will be examined.
Time frame: Up to 5 days
The number of entrants identified having an acute HIV infection will be examined.
Time frame: Up to 5 days
The time (in hours) from the positive test result in persons not previously diagnosed and receipt of test report.
Time frame: Up to Jail Discharge
The time (in days) from entry until receipt of first dose of antiviral in the jail, for PLWH.
Time frame: 6 months after positive HIV intake test
For all PLWH, the time (in days) from entry to achieving viral suppression, if not suppressed at baseline.
Time frame: Up to Jail Discharge
For all PLWH, the time (in days) from intake to meeting the discharge planner.
Time frame: 2 months after jail release, 6 months after jail release
For those consenting to the first sub-study, the number of high-risk persons who test negative for HIV who successfully link to PrEP within 2 months of jail release and stay on PrEP for at least 6 months will be examined.
Time frame: 1 year
For persons living with HIV who consent to the second sub-study, the percentage of persons previously and newly diagnosed who make clinic visits at least once every 6 months will be examined.
Time frame: 6 months
For persons living with HIV who consent to the second sub-study, the percentage of persons previously and newly diagnosed who are virally suppressed 6 months after sub-study enrollment.
Time frame: 6 months
A cost-effectiveness analysis using the intermediate process measures will be conducted. Units of resource items, such as tests and staff time, will be multiplied by their unit costs to calculate total costs. Wage ranges provided by DOC and Unity Healthcare will be used to price staff time; market values will be used for all other items. Costs will then be summed by testing strategy.
Emory University
Other
Linking Persons With HIV, Discharged From Jail, With Community Care: a Direct Comparison of the Costs and Effects of Three HIV Management Strategies in the District of Columbia Department of Corrections
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03823209
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Cleveland, Ohio, United States
View Trial DetailsNCT06176859
ART, Acquired Immunodeficiency Syndrome
Durban, KwaZulu-Natal, South Africa
View Trial DetailsNCT02344680
Acquired Immunodeficiency Syndrome, Adenocarcinoma
Lusaka, Lusaka Province, Zambia
View Trial DetailsNCT04704336
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
St Louis, Missouri, United States
View Trial Details